Ann: Phosphagenics Further Expands Pain Portfolio, page-65

re: Ann: Phosphagenics Further Expands Pain P... I think any talk of a capital raising are quite premature. As of 1st January, they had $23mill in current assets and $1.5mill in current liabilities which equals $21.5mill. $7.5mill coming in this calendar year plus let's say $3mill in revenues from other products (I consider this will probably be a little conservative) and it's $32mill to play with. We know the Phase 3 trials are going to be quite expensive but there is a chance that a deal will be struck before commencement of Phase 3.

I just don't see any rush or panic or need whatsoever for the company to need to consider a CR within the next 12 months and certainly I don't think any shareholders (including Harry and Esra) would want another one at these prices.